ArticleWorld journal of stem cells2025
First-ever stem cell therapy restores insulin independence in type 1 diabetes: A medical milestone.
Article in World journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Type 1 Diabetes Mellitus Pathogenesis: Mechanisms, Early Diagnostic Strategies, and Emerging Therapeutic Approaches.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Stem Cells to Organoids: Pioneering the Future of Regenerative Therapies.Stem cell reviews and reports · 2026Review
- Next-generation microneedle platforms for site-specific management of diabetic neuropathy.Diabetology & metabolic syndrome · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stem cell therapy has emerged as a groundbreaking treatment approach, particularly for type 1 diabetes, where the autoimmune destruction of beta cells necessitates regenerative strategies to restore insulin production. This article focuses on the recent medical milestone in which autologous stem cell therapy led to insulin independence in a type 1 diabetes patient. This article explores the role of stem cell therapy in reversing diabetes, focusing on the recent medical milestone in which stem cell therapy successfully reversed diabetes in a patient. Stem cells, particularly induced pluripotent stem cells, are used to regenerate pancreatic cells that produce insulin, thereby potentially eliminating the need for insulin injections. The study highlights both the promises and challenges of using stem cell therapy for diabetes including concerns about durability of the response, safety and long-term functionality of generated beta cells. Clinical trials and the ethical considerations of using stem cells are also discussed, along with future directions for stem cell-based diabetes therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.